Dr. Nikolai Tankovich
Copyright: Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！ 京ICP备19006400号-1 Powered by 300.cn
Links：
Founded in March 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (“Jiuzhitang Maker”) is a biotechnology company focused on the manufacture, R&D and sales of stem cell-based drugs and regenerative care products. Jiuzhitang Maker was established with an investment of 200 million yuan made by Yonghe Qihang Fund launched by Jiuzhitang Co., Ltd. (“Jiuzhitang”, stock code: sz000989). Jiuzhitang Maker has built a large-scale allogeneic stem cells R&D and manufacturing facility that meets Chinese, US and EU cGMP standards in Beijing’s Daxing Biomedicine Industry Park, the first of its kind in Beijing. With the production and office area totalling about 4500m2, the facility has four separate Grade B+A clean zones dedicated to the manufacture of clinical grade stem cell products that comply with Chinese and US drug application requirements.
About Us
In the US, Stemedica and its partners have launched 8 clinical trials using stem cells to treat ischemic stroke, skin photoaging, non-ischemic chronic heart failure, Alzheimer’s disease, traumatic brain injury, heart failure requiring LVAD, acute myocardial infarction and lung injury caused by COVID-19. Trials on ischemic stroke and chronic heart failure have completed Phase IIa and published many high level academic papers, while the one on Alzheimer’s is the first US study with approval to treat this debilitating disorder using stem cells. In addition, Stemedica has 11 clinical studies in progress in Switzerland, Kazakhstan, Mexico, China, etc. In particular, the Kazak study treating acute heart failure with Stemedica manufactured it-hMSCs has completed, rendering the product being approved and listed by the Ministry of Health of Kazakhstan as a therapy to this disease in September 2018.
Clinical Indications
Chronic heart failure
Acute myocardial infarction
Acute myocardial infarction is myocardial necrosis caused by acute, persistent ischemia and hypoxia in...
Skin aging is a series of complex biological changes that involve both endogenous and ...
Cutaneous photoaging
Traumatic brain/spinal injury
Traumatic brain/spinal injury is a penetrating injury mainly caused by traffic accidents, work...
Alzheimer's disease, commonly known as senile dementia, is a common neurodegenerative ...
Alzheimer's disease
Chronic heart failure
Chronic heart failure lies in the end stage of development of many cardiovascular diseases...
Cerebral stroke
Commonly known as apoplexy, cerebral stroke is the second most common cause of death and...
Dr. Alex Kharazi
Dr. Lev Verkh
Advisors
Jiuzhitang Maker is supported by global expertise in areas of stem cells research and development of clinical programs on pharmaceuticals. Dr. Nikolai Tankovich is a recognized innovator, researcher and educator for laser applications in medicine, cancer vaccines, stem cell therapies and other medical related disciplines. Dr. Alex Kharazi is a distinguished expert on cell therapy and immunotherapy. He has been a faculty member at the University of Southern California in Los Angeles and Chief Scientist at an Immunotherapy Laboratory......
Jiuzhitang Maker signed the Cooperation Agreement on Jointly Building Jiuzhitang-ALTACO International Medical center for Stem Cells with Kazakhstan-based LLP "ALTACO-XXI" in the China-Kazakhstan Horgos Frontier International Cooperation Center.
Jiuzhitang Maker selected as one of the Ten Key companies received “Comprehensive Service Package” offered by Daxing District
Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction
Jiuzhitang Maker signed the Agreement on Co-construction of Stem Cells Clinical Research Base with Beijing Tiantan Hospital.
Company News